Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2016

01-01-2016 | Bone and Soft Tissue Sarcomas

Metastatic Potential of Grade I Chondrosarcoma of Bone: Results of a Multi-institutional Study

Authors: Dimosthenis Andreou, MD, Magdalena M. Gilg, MD, Georg Gosheger, MD, Mathias Werner, MD, Jendrik Hardes, MD, Daniel Pink, MD, Andreas Leithner, MD, Per-Ulf Tunn, MD, Arne Streitbürger, MD

Published in: Annals of Surgical Oncology | Issue 1/2016

Login to get access

Abstract

Background

Little is known about the metastatic potential of low-grade chondrosarcoma. This study was designed to evaluate the rate of metastasis to identify possible risk factors.

Methods

The files of 225 patients with newly diagnosed, grade I chondrosarcoma of bone treated between 1975 and 2012 were retrospectively analyzed. Median follow-up was 80 months for survivors (range 24–445 months). Nonparametric analyses were performed with the Mann–Whitney U test. Survival curves were calculated with the Kaplan–Meier method and compared with the log-rank test.

Results

Fourteen patients developed metastases after a median of 49 months. Metastasis-free survival probability (MFS) was 95 % at 5 years and 92 % at 10 years. Post-metastasis survival probability amounted to 27 % after 5 years. Tumor size at diagnosis (P = 0.698) and surgical margin width (P = 0.514) had no influence on MFS. Patients who developed local recurrences had a significantly lower 10-year MFS than patients without recurrences (69 % vs. 99 %, P < 0.001). Patients with grade I recurrences had a significantly poorer MFS than patients without recurrences (P = 0.013) but a significantly higher MFS than patients with grade II recurrences (P = 0.006). Patients with thoracic wall tumors had a significantly lower 10-year MFS of 66 % compared with patients with tumors of the upper (100 %, P < 0.001) and lower extremity (93 %, P = 0.033).

Conclusions

The biological behavior of low-grade chondrosarcoma appears to be more consistent with the WHO definition of rarely metastasizing bone tumors, rather than the one of locally aggressive neoplasms. Thoracic wall tumors and the development of local recurrences were associated with a higher metastasis rate in this study.
Literature
1.
Hogendoorn PCW, Bovée JVMG, Nielsen GP. Chondrosarcoma (grades I-III), including primary and secondary variants and periosteal chondrosarcoma. In: Fletcher C, Bridge J, Hogendoorn P, Mertens F, eds. WHO classification of tumours of soft tissue and bone. Lyon: International Agency for Research on Cancer; 2013.
2.
Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008;13(3):320–9.PubMedCrossRef
3.
Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40(2):818–31.PubMedCrossRef
4.
Bjornsson J, McLeod RA, Unni KK, Ilstrup DM, Pritchard DJ. Primary chondrosarcoma of long bones and limb girdles. Cancer. 1998;83(10):2105–19.PubMedCrossRef
5.
Andreou D, Ruppin S, Fehlberg S, Pink D, Werner M, Tunn PU. Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-up. Acta Orthop. 2011;82(6):749–55.PubMedPubMedCentralCrossRef
6.
Leerapun T, Hugate RR, Inwards CY, Scully SP, Sim FH. Surgical management of conventional grade I chondrosarcoma of long bones. Clin Orthop Rel Res. 2007;463:166–72.
7.
Streitburger A, Ahrens H, Balke M, et al. Grade I chondrosarcoma of bone: the Munster experience. J Cancer Res Clin Oncol. 2009;135(4):543–50.PubMedCrossRef
8.
Funovics PT, Panotopoulos J, Sabeti-Aschraf M, et al. Low-grade chondrosarcoma of bone: experiences from the Vienna Bone and Soft Tissue Tumour Registry. Int Orthop. 2011;35(7):1049–56.PubMedPubMedCentralCrossRef
9.
Hickey M, Farrokhyar F, Deheshi B, Turcotte R, Ghert M. A systematic review and meta-analysis of intralesional versus wide resection for intramedullary grade I chondrosarcoma of the extremities. Ann Surg Oncol. 2011;18(6):1705–9.PubMedCrossRef
10.
Verdegaal SH, Brouwers HF, van Zwet EW, Hogendoorn PC, Taminiau AH. Low-grade chondrosarcoma of long bones treated with intralesional curettage followed by application of phenol, ethanol, and bone-grafting. J Bone Joint Surg Am. 2012;94(13):1201–7.PubMedCrossRef
11.
Campanacci DA, Scoccianti G, Franchi A, et al. Surgical treatment of central grade 1 chondrosarcoma of the appendicular skeleton. J Orthop Traumatol. 2013;14(2):101–7.PubMedPubMedCentralCrossRef
12.
Grimer RJ, Hogendoorn PCW, Vanel D. Tumours of bone: Introduction. In: Fletcher C, Bridge J, Hogendoorn P, Mertens F, eds. WHO classification of tumours of soft tissue and bone. Lyon: International Agency for Research on Cancer; 2013.
13.
Rizzo M, Ghert MA, Harrelson JM, Scully SP. Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome. Clin Orthop Rel Res. 2001(391):224–33.CrossRef
14.
Kaplan E, Maier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
15.
Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep Part 1. 1966;50(3):163–170.
16.
Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Rel Res. 1986(204):9–24.
17.
Skeletal Lesions Interobserver Correlation among Expert Diagnosticians Study Group. Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones. J Bone Joint Surg Am. 2007;89(10):2113–23.CrossRef
18.
Eefting D, Schrage YM, Geirnaerdt MJ, et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol. 2009;33(1):50–7.PubMedCrossRef
19.
Schwab JH, Wenger D, Unni K, Sim FH. Does local recurrence impact survival in low-grade chondrosarcoma of the long bones? Clin Orthop Rel Res. 2007;462:175–80.CrossRef
20.
Taminiau AHM, Bovée JVMG, van Rijswijk CSP, Gelderblom HAJ, van de Sande MAJ. Cartilage Tumours of Bone. In: Bentley G, ed. European surgical orthopaedics and traumatology the EFORT textbook. Berlin: Springer; 2014. doi:10.​1007/​978-3-642-34746-7.
21.
Berrington de Gonzalez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169(22):2071–7.PubMedCrossRef
22.
Puri A, Gulia A, Hawaldar R, Ranganathan P, Badwe RA. Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial. Clin Orthop Rel Res. 2014;472(5):1568–75.CrossRef
Metadata
Title
Metastatic Potential of Grade I Chondrosarcoma of Bone: Results of a Multi-institutional Study
Authors
Dimosthenis Andreou, MD
Magdalena M. Gilg, MD
Georg Gosheger, MD
Mathias Werner, MD
Jendrik Hardes, MD
Daniel Pink, MD
Andreas Leithner, MD
Per-Ulf Tunn, MD
Arne Streitbürger, MD
Publication date
01-01-2016
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 1/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4852-1

Other articles of this Issue 1/2016

Annals of Surgical Oncology 1/2016 Go to the issue

Gastrointestinal Oncology

Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy

Gynecologic Oncology

Comparison of Lower Extremity Edema in Locally Advanced Cervical Cancer: Pretreatment Laparoscopic Surgical Staging with Tailored Radiotherapy Versus Primary Radiotherapy

Hepatobiliary Tumors

A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases

Gynecologic Oncology

Tumor Size, an Additional Prognostic Factor to Include in Low-Risk Endometrial Cancer: Results of a French Multicenter Study

Breast Oncology

Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment

Thoracic Oncology

Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?